Monitoring response and resistance to the novel arsenical darinaparsin in an AML patient

• Autori principali: Torsten Holm eNielsen (Autore), Nathalie eJohnson (Autore), Nicolas eGarnier (Autore), Stanley eKwan (Autore), Lu eYao (Autore), Eftihia eCocolakis (Autore), Josée eHébert (Autore), Robert A. Morgan (Autore), Éric ePaquet (Autore), Kevin P. Callahan (Autore), Craig T. Jordan (Autore), Sarit eAssouline (Autore), Wilson H. Miller (Autore), Koren K. Mann (Autore)
• Natura: Libro
• Pubblicazione: Frontiers Media S.A., 2013-02-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Acute myeloid leukemia (AML) with inversion of chromosome 3 is characterized by overexpression of EVI1 and carries a dismal prognosis. Arsenic-containing compounds have been described to be efficacious in malignancies overexpressing EVI1. Here we describe a case of AML with inv(3)(q21q26.2) treated...